FDA Approves New Drug to Fight Severe Breast Cancer


by Joshua Daly - Date: 2007-03-15 - Word Count: 288 Share This!

On March 13, the FDA approved a new drug that in recent clinical trials, delayed the spread of advanced breast cancer who were no longer showing any reaction to Hereceptin. Hereceptin is a drug which affectively combats cancerous tumors filled with too much HER-2 protein.

The new drug called Tykerb, couple with chemotherapy, has show in clinical trials to do a better job of fighting breast cancer than chemo alone.

Dr. Steven Galson, director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research said, "Today's approval is a step forward in making new treatments available for patients who have progression of their breast cancer after treatment with some of the most effective breast cancer therapies available. New targeted therapies such as Tykerb are helping expand options for patients."

I hope the results of this study will save the lives of the nearly 10,000 women who die each year from this type of cancer. According to HealthDay, "The drug was tested in a trial involving 400 women with advanced or metastatic breast cancer that was HER2 positive. Common side effects included diarrhea, nausea, vomiting, and rash. A small percentage of participants also had a decrease in heart function that may have been characterized by shortness of breath."

Although this medication may go on to save the lives of many women, the FDA should not allow companies who have interest in the outcome of the study be the one who funds and conducts it. Anyone who has interest in the outcome of any event will always do what is in their power to protect their interest. Like the old adage goes. "You ain't cheatin, You ain't tryin ."

Click here for more information on ordering online prescriptions from discount pharmacies.

Related Tags: online pharmacies, breast cancer, online pharmacy, fda, tykerb

Your Article Search Directory : Find in Articles

© The article above is copyrighted by it's author. You're allowed to distribute this work according to the Creative Commons Attribution-NoDerivs license.
 

Recent articles in this category:



Most viewed articles in this category: